Alisertib, an Aurora a Kinase inhibitor, induces autophagy of colorectal cancer cells and its relationship with p53 expression

doi:10.3969/j.issn.1009-976X.2021.01.014

Abstract

Abstract: Objective To explore the effect of Alisertib （ALS） on human colorectal cancer Caco-2 and HT29 cells in inducing autophagy and its relationship with the expression of p53. Methods In this study, human colorectal cancer Caco-2 and HT29 cells were used for experiments. The experimental groups were treated with 0.1, 1, and 5 μmol/L ALS and the control group was treated with the same concentration of DMSO. The autophagy rate of cells was detected by flow cytometry. The protein expression levels of key regulatory molecules in the process of cell autophagy were examined by wester blotting. Results Compared with the control group, the autophagy rate of Caco-2 cells in the 0.1 and 1 μmol/L Alisertib groups increased to 26.4% and 26.8% （P<0.01）. The autophagy rate of HT29 cells in the 1 and 5 μmol/L ALS groups increased to 36.8% and 42.6% （P<0.01）. Caco-2 cells did not express p53 protein, while HT29 cells expressed p53 protein. Compared with the control group, the ratio of p-PI3K/PI3K, p-Akt/Akt and p-p38/p38 in Caco-2 cells after treatment with 1, 5 μmol/L alisertib decreased to 62.6%, 45.2%, 30.1%, 38.2% and 49.0%, 30.4% （P<0.01）, while the ratio of LC3-II/LC3-I increased by 32.6%, 46.8% （P<0.01）. 1, 5 μmol/L Alisertib caused the p-PI3K/PI3K and p-Akt/Akt ratios of HT29 cells to decrease to 70.9%, 66.3% and 85.2%, 27.2% （P<0.01）, while the ratio of p38/p38 and LC3-Ⅱ/LC3-I increased by 2.1 times, 2.0 times and 78.5%, 84.8% （P<0.05）. Compared with the 5 μmol/L Alisertib group, 10 μmol/L SB202190+5 μmol/L Alisertib increased the apoptotic rate of HT29 cells by 64.7% （P<0.001）, while the apoptotic rate of Caco-2 cells did not change significantly. Conclusion Alisertib induces autophagy in Caco-2 and HT29 cells by inhibiting PI3K/Akt signaling pathway. Alisertib activates the p38 MAPK signaling pathway in HT29 but inhibits the p38 MAPK signaling pathway in Caco-2 cells, which may be related to the expresion of p53 protein.

Key words: Alisertib, Aurora A, p53, colorectal cancer, autophagy

摘要： 目的探讨Alisertib（ALS）对人结直肠癌Caco-2和HT29细胞的诱导自噬的作用及与p53 表达状态间的关系。方法本研究采用人结直肠癌Caco-2和HT29细胞进行实验。实验组用0.1、1、5 μmol/L ALS而对照组用同浓度的DMSO处理细胞。流式细胞术检测细胞的自噬率,Wester Blotting法检测细胞自噬过程中关键调节分子的蛋白表达。结果与对照组比较,0.1、1 μmol/L Alisertib组Caco-2细胞自噬率增加,分别为26.4%和26.8%（P<0.01）。1、5 μmol/L ALS组HT29细胞自噬率增加,分别为36.8%和42.6%（P<0.01）。Caco-2细胞不表达p53蛋白,而HT29细胞表达p53蛋白。与对照组比较,1、5μmol/L Alisertib引起Caco-2细胞的p-PI3K/PI3K、p-Akt/Akt和p-p38/p38的比值分别降低为对照组的62.6%、45.2%,30.1%、38.2%和49.0%、30.4%（P<0.01）,LC3-Ⅱ/LC3-I的比值升高32.6%、46.8%（P<0.01）。与对照组比较,1、5 μmol/L Alisertib引起HT29细胞的p-PI3K/PI3K、p-Akt/Akt的比值分别降低为对照组的70.9%、66.3%和85.2%、27.2%（P<0.01）,p-p38/p38和LC3-II/LC3-I的比值升高2.1倍、2.0倍和78.5%、84.8%（P<0.05）。与5 μmol/L Alisertib组比较,10 μmol/L SB202190+5 μmol/L Alisertib引起HT29细胞凋亡率升高64.7%（P<0.001）,而Caco-2细胞凋亡率无明显变化。结论 Alisertib抑制了PI3K/Akt信号通路,诱导了Caco-2和HT29细胞发生细胞自噬。Alisertib对p38 MAPK信号通路的影响不同,激活了HT29而抑制了Caco-2细胞的p38 MAPK信号通路,可能与p53蛋白是否表达有关。

关键词: Alisertib, Aurora A, p53, 结直肠癌, 自噬

CLC Number:

REN Bao-jun, JU Yong-le, FENG Jing, CHEN Shu-xiang, LIU Jia-xuan, LUO Zhen-tao, WANG Jia-zhi, YANG Fan, LI De-zhi, DONG Bo-ye, GENG Yan. Alisertib, an Aurora a Kinase inhibitor, induces autophagy of colorectal cancer cells and its relationship with p53 expression[J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 82-86.

任宝军, 剧永乐, 封静, 陈淑香, 刘家旋, 罗振涛, 王家智, 杨帆, 李德智, 董博业, 耿岩. Aurora A激酶抑制剂Alisertib诱导结直肠癌细胞自噬的作用及与p53表达间的关系[J]. 岭南现代临床外科, 2021, 21(01): 82-86.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Kogiso M, Qi L, Braun FK, et al.Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX Models[J]. Clin Cancer Res, 2018, 24(9): 2159-2170.
[3] Wang F, Li H, Yan XG, et al.Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells[J]. Drug Des Devel Ther, 2015, 9: 575-601.
[4] Ding YH, Zhou ZW, Ha CF, et al.Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells[J]. Drug Des Devel Ther, 2015, 9: 425-64.
[5] Mosse YP, Fox E, Teachey DT, et al.A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)[J]. Clin Cancer Res, 2019, 25(11):3229-3238.
[6] Beltran H, Oromendia C, Danila DC, et al.A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers[J]. Clin Cancer Res, 2019, 25(1): 43-51.
[7] Klionsky DJ and Emr SD. Autophagy as a regulated pathway of cellular degradation[J]. Science, 2000, 290(5497): 1717-1721.
[8] Mathew R, Kongara S, Beaudoin B, et al.Autophagy suppresses tumor progression by limiting chromosomal instability[J]. Genes Dev, 2007, 21(11): 1367-1381.
[9] Mizushima N and Komatsu M. Autophagy: renovation of cells and tissues[J]. Cell, 2011, 147(4): 728-41.
[10] Danial NN, Korsmeyer SJ.Cell death: critical control points[J]. Cell, 2004, 116(2): 205-219.
[11] Alers S, Loffler AS, Wesselborg S, et al.Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks[J]. Mol Cell Biol, 2012, 32(1): 2-11.
[12] Tang G, Yue Z, Talloczy Z, et al.Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways[J]. Hum Mol Genet, 2008, 17(11): 1540-1555.
[13] Yuan CX, Zhou ZW, Yang YX, et al.Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells[J]. Drug Des Devel Ther, 2015, 9: 487-508.
[14] Niu NK, Wang ZL, Pan ST, et al.Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway[J]. Drug Des Devel Ther, 2015, 9: 1555-1584.
[15] Li JP, Yang YX, Liu QL, et al.The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells[J]. Drug Des Devel Ther, 2015, 9: 1627-52.